← Back to Patent Explorer
EP0109285A1 Expired / Lapsed EP ⏱️ 0.0 years remaining

6,7-Dihydro-8-(imidazol-1-yl)-5-methyl-1-oxo-1H,5H-benzo(ij)quinolizine-2-carboxylic acids and derivatives

Assignee: Riker Laboratories Inc
•
Filing: 1983-11-11
•
Granted: —
•
Expires: 2003-11-11
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Certain 6,7-dihydro-8-limidazol-1-yp-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylic acids are disclosed as potent antimicrobial agents with an unusual spectrum of activity. Esters, acyl chlorides, alkylaminoalkyl ester salts, salts of a nitrogen atom of the imidazole ring, and pharmaceutically acceptable carboxylate salts are also disclosed. Novel synthetic intermediates are also described.

Inventors

  • 👤 John F. c/o Riker Laboratories Inc. Gerster

Bibliographic Details

Application Number —
Jurisdiction EP
Data Source google_patents
Last Synchronized 2026-10-27 15:48
CPC Classifications
C; C07; C07D; C07D471/00; C07D471/02; C07D471/04; C07D231/00; C07D231/02; C07D231/10; C07D231/12; A; A61; A61P; A61P31/00; A61P31/04; C07D215/00; C07D215/02; C07D215/16; C07D215/38; C07D233/00; C07D233/54; C07D233/56; C07D249/00; C07D249/02; C07D249/08; C07D455/00; C07D455/03; C07D455/04

Claims Analysis

Total Claims: 22
Claim 1
Independent Claim 52 words
A compound of the formula wherein X is hydrogen or halogen selected from fluorine, chlorine or bromine; or a derivative selected from the group consisting of an ester, the acyl chloride, an alkylaminoalkyl ester salt, a salt involving a nitrogen atom of the imidazole ring, and a pharmaceutically acceptable carboxylate salt thereof.
Claim 2
Dependent Claim 52 words
A compound of the formula wherein X is hydrogen or halogen selected from fluorine, chlorine or bromine; or a derivative selected from the group consisting of an ester, the acyl chloride, an alkylaminoalkyl ester salt, a salt involving a nitrogen atom of the imidazole ring, and a pharmaceutically acceptable carboxylate salt thereof.
Claim 3
Dependent Claim 21 words
A compound according to Claim 1 which is a carboxylate salt selected from an alkali metal and alkaline earth carboxylate salts.
Claim 4
Dependent Claim 12 words
The compound 6,7-dihydro-8-(imidazol-l-yl)-9-fluoro-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylic acid or a salt thereof according to Claim 1.
Claim 5
Dependent Claim 19 words
A pharmaceutical composition comprising an effective amount of a compound according to Claim 1 and a pharmaceutically acceptable carrier.
Claim 6
Dependent Claim 23 words
A method of inhibiting the growth of bacteria, comprising contacting said bacteria with an effective amount of a compound according to Claim 1.
Claim 7
Dependent Claim 22 words
A compound of the formula wherein X is hydrogen or halogen; and Q is hydrogen or -CH=C(C0 2 CH 2 CH 3)2.
Claim 8
Dependent Claim 22 words
A compound of the formula wherein X is hydrogen or halogen; and Q is hydrogen or -CH=C(C0 2 CH 2 CH 3)2.
Claim 9
Dependent Claim 33 words
A compound of the formula wherein X is hydrogen or halogen; and Y is imidazol-1-yl, 2-mercaptoimidazol-1-yl, -N=C=S or, wherein each R 1 is independently an alkyl group containing 1 to about 4 carbons.
Claim 10
Dependent Claim 33 words
A compound of the formula wherein X is hydrogen or halogen; and Y is imidazol-1-yl, 2-mercaptoimidazol-1-yl, -N=C=S or, wherein each R 1 is independently an alkyl group containing 1 to about 4 carbons.
Claim 11
Dependent Claim 196 words
A process for the preparation of a 6,7-dihydro-8-(imidazol-1-yl)-5-methyl-1-oxo-1H,5H-benzo-[ij]quinolizine-2-carboxylic acid of the formula: wherein X is hydrogen or halogen, comprising the steps of a) cyclizing an N-(2,2-dialkoxyethyl)-N'-(2-methylquinolin-5-yl)thiourea of the formula wherein X is as defined above and each R 1 is independently an alkyl group containing 1 to about 4 carbon atoms, to provide a 5-(2-mercaptoimidazol-1-yl)-2-methylquinoline of the formula wherein X is as defined above, and b) desulfurizing the 5-(2-mercaptoimidazol-l-yl)-2-methylquinoline from step a) to provide a 5-(imidazol-1-yl)-2-methylquinoline of the formula wherein X is as defined above, and c) reducing the 5-(imidazol-1-yl)-2-methylquinoline from step b) to provide a 5-(imidazol-1-yl)-1,2,3,4-tetrahydro-2-methylquinoline of the formula wherein X is as defined above, and d) condensing the 5-(imidazol-1-yl)-1,2,3,4-tetrahydro-2-methylquinoline from step c) with a diester of an alkoxymethylenemalonic acid of the formula wherein alk is an alkyl group containing 1 to about 4 carbon atoms and each R 2 is independently an alkyl group containing 1 to about 4 carbon atoms, or the R 2 . s together form an isopropyl radical, to provide an antermediate of the formula wherein X and each R 2 are as defined above, and e) cyclizing and deesterifying the imtermediate from step d) to provide said 6,7-dihydro-8-(imidazol-1-yl)-5-methyl-1-oxo-1H,5H-benzo-[ij]quinolizine-2-carboxylic acid.
Claim 12
Dependent Claim 196 words
A process for the preparation of a 6,7-dihydro-8-(imidazol-1-yl)-5-methyl-1-oxo-1H,5H-benzo-[ij]quinolizine-2-carboxylic acid of the formula: wherein X is hydrogen or halogen, comprising the steps of a) cyclizing an N-(2,2-dialkoxyethyl)-N'-(2-methylquinolin-5-yl)thiourea of the formula wherein X is as defined above and each R 1 is independently an alkyl group containing 1 to about 4 carbon atoms, to provide a 5-(2-mercaptoimidazol-1-yl)-2-methylquinoline of the formula wherein X is as defined above, and b) desulfurizing the 5-(2-mercaptoimidazol-l-yl)-2-methylquinoline from step a) to provide a 5-(imidazol-1-yl)-2-methylquinoline of the formula wherein X is as defined above, and c) reducing the 5-(imidazol-1-yl)-2-methylquinoline from step b) to provide a 5-(imidazol-1-yl)-1,2,3,4-tetrahydro-2-methylquinoline of the formula wherein X is as defined above, and d) condensing the 5-(imidazol-1-yl)-1,2,3,4-tetrahydro-2-methylquinoline from step c) with a diester of an alkoxymethylenemalonic acid of the formula wherein alk is an alkyl group containing 1 to about 4 carbon atoms and each R 2 is independently an alkyl group containing 1 to about 4 carbon atoms, or the R 2 . s together form an isopropyl radical, to provide an antermediate of the formula wherein X and each R 2 are as defined above, and e) cyclizing and deesterifying the imtermediate from step d) to provide said 6,7-dihydro-8-(imidazol-1-yl)-5-methyl-1-oxo-1H,5H-benzo-[ij]quinolizine-2-carboxylic acid.
Claim 13
Dependent Claim 46 words
A process in accordance with Claim 8, wherein said N-(2,2-dialkoxyethyl)-N'-(2-methylquinolin-5-yl)-thiourea used in step a) is obtained by condensing a 5-amino-2-methylquinoline of the formula wherein X is as defined in Claim 8, with a 2,2-dialkoxyethylisothiocyanate of the formula wherein R 1 is as defined in Claim 8.
Claim 14
Dependent Claim 73 words
A process in accordance with Claim 8, wherein said N-(2,2-dialkoxyethyl-N'-(2-methylquinolin-5-yl)thiourea used in step a) is obtained by first recting a 5-amino-2-methylquinoline of the formula wherein X is as defined in Claim 8, with thiophosgene to provide a 5-isothiocyanato-2-methylquinoline of the formula wherein X is as defined above, and then reacting said 5-isothiocyanato-2-methylquinoline with an aminoacetaldehyde dialkyl acetal of the formula wherein R 1 is as defined in Claim 8 to provide said N-(2,2-dialkoxyethyl)-N'-(2-methylquinolin-5-yl)-thiourea.
Claim 15
Dependent Claim 17 words
A compound according to claim 1 for use in treating a microbial infection in humans or animals.
Claim 16
Independent Claim 240 words
A method for the preparation of a compound of the formula wherein X is hydrogen or halogen selected from fluorine, chlorine or bromine; or a derivative which is an ester, the acyl chloride, an alkylaminoalkyl ester salt, a salt involving a nitrogen atom of the imidazole ring, or a pharmaceutically acceptable carboxylate salt thereof, comprising the steps of : a) cyclizing an N-(2,2-dialkoxyethyl)-N'-(2-methylquinolin-5-yl)thiourea of the formula wherein X is as defined above and each R l is independently an alkyl group containing 1 to about 4 carbon atoms, to provide a 5-(2-mercaptoimidazol-1-yl)-2-methylquinoline of the formula wherein X is as defined above, and b) desulfurizing the 5-(2-mercaptoimidazol-l-yl)-2-methylquinoline from step a) to provide a 5-(imidazol-1-yl)-2-methylquinoline of the formula wherein X is as defined above, and c) reducing the 5-(imidazol-1-yl)-2-methylquinoline from step b) to provide a 5-(imidazol-1-yl)-1,2,3,4-tetrahydro-2-methylquinoline of the formula wherein X is as defined above, and d) condensing the 5-(imidazol-1-yl)-1,2,3,4-tetrahydro-2-methylquinoline from step c) with a diester of an alkoxymethylenemalonic acid of the formula wherein alk is an alkyl group containing 1 to about 4 carbon atoms and each R 2 is independently an alkyl group containing 1 to . about 4 carbon atoms, or the R 2 's together form an isopropyl radical, to provide an antermediate of the formula wherein X and each R 2 are as defined above, and e) cyclizing and deesterifying the imtermediate from step d) to provide said 6,7-dihydro-8- f) and, if necessary, forming the appropriate derivative.
Claim 17
Independent Claim 240 words
A method for the preparation of a compound of the formula wherein X is hydrogen or halogen selected from fluorine, chlorine or bromine; or a derivative which is an ester, the acyl chloride, an alkylaminoalkyl ester salt, a salt involving a nitrogen atom of the imidazole ring, or a pharmaceutically acceptable carboxylate salt thereof, comprising the steps of : a) cyclizing an N-(2,2-dialkoxyethyl)-N'-(2-methylquinolin-5-yl)thiourea of the formula wherein X is as defined above and each R l is independently an alkyl group containing 1 to about 4 carbon atoms, to provide a 5-(2-mercaptoimidazol-1-yl)-2-methylquinoline of the formula wherein X is as defined above, and b) desulfurizing the 5-(2-mercaptoimidazol-l-yl)-2-methylquinoline from step a) to provide a 5-(imidazol-1-yl)-2-methylquinoline of the formula wherein X is as defined above, and c) reducing the 5-(imidazol-1-yl)-2-methylquinoline from step b) to provide a 5-(imidazol-1-yl)-1,2,3,4-tetrahydro-2-methylquinoline of the formula wherein X is as defined above, and d) condensing the 5-(imidazol-1-yl)-1,2,3,4-tetrahydro-2-methylquinoline from step c) with a diester of an alkoxymethylenemalonic acid of the formula wherein alk is an alkyl group containing 1 to about 4 carbon atoms and each R 2 is independently an alkyl group containing 1 to . about 4 carbon atoms, or the R 2 's together form an isopropyl radical, to provide an antermediate of the formula wherein X and each R 2 are as defined above, and e) cyclizing and deesterifying the imtermediate from step d) to provide said 6,7-dihydro-8- f) and, if necessary, forming the appropriate derivative.
Claim 18
Dependent Claim 46 words
A process in accordance with Claim 1, wherein said N-(2,2-dialkoxyethyl)-N'-(2-methylquinolin-5-yl)-thiourea used in step a) is obtained by condensing a 5-amino-2-methylquinoline of the formula wherein X is as defined in Claim 1, with a 2,2-dialkoxyethylisothiocyanate of the formula wherein R 1 is as defined in Claim 1.
Claim 19
Dependent Claim 75 words
3 .. A process in accordance with Claim 1, wherein said N-(2,2-dialkoxyethyl-N'-(2-methylquinolin-5-yl)thiourea used in step a) is obtained by first reacting a 5-amino-2-methylquinoline of the formula wherein X is as defined in Claim 1, with thiophosgene to provide a 5-isothiocyanato-2-methylquinoline of the formula wherein X is as defined above, and then reacting said 5-isothiocyanato-2-methylquinoline with an aminoacetaldehyde dialkyl acetal of the formula wherein R 1 is as defined in Claim 1 to provide said N-(2,2-dialkoxyethyl)-N'-(2-methylquinolin-5-yl)-thiourea.
Claim 20
Dependent Claim 22 words
A method according to claim 1 in which the carboxylate salt formed is an alkali metal or an alkaline earth carboxylate salt.
Claim 21
Dependent Claim 29 words
A method according to claim 1 wherein the final product is formed into a pharmaceutical composition by combining an effective amount of the compound with a pharmaceutically acceptable carrier.
Claim 22
Dependent Claim 24 words
A method of inhibiting the growth of bacteria, comprising contacting said bacteria with an effective amount of a compound as defined in claim 1.

References Cited (Backward Citations)

DE3031767A1 Cited
GB2062627A Cited
DE3144455A1 Cited
GB2091726A Cited

USPTO Annuity & Maintenance Windows

Maintenance schedule is calculated for granted US utility patents.

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag